• bitcoinBitcoin(BTC)$64,911.00-0.02%
  • ethereumEthereum(ETH)$1,826.250.21%
  • tetherTether(USDT)$1.000.00%
  • binancecoinBNB(BNB)$592.750.20%
  • usd-coinUSDC(USDC)$1.000.00%
  • rippleXRP(XRP)$0.960.03%
  • solanaSolana(SOL)$72.611.20%
  • tronTRON(TRX)$0.3049650.45%
  • Figure HelocFigure Heloc(FIGR_HELOC)$1.040.00%
  • HyperliquidHyperliquid(HYPE)$69.935.40%
  • zcashZcash(ZEC)$914.392.78%
  • moneroMonero(XMR)$496.781.26%
  • dogecoinDogecoin(DOGE)$0.0590580.32%
  • leo-tokenLEO Token(LEO)$9.331.32%
  • USDSUSDS(USDS)$1.000.12%
  • whitebitWhiteBIT Coin(WBT)$62.79-0.19%
  • chainlinkChainlink(LINK)$9.17-0.10%
  • cardanoCardano(ADA)$0.1540110.04%
  • stellarStellar(XLM)$0.138732-0.93%
  • Ethena USDeEthena USDe(USDE)$1.00-0.01%
  • RainRain(RAIN)$0.00620780.53%
  • daiDai(DAI)$1.000.01%
  • nearNEAR Protocol(NEAR)$3.241.83%
  • bitcoin-cashBitcoin Cash(BCH)$208.35-0.30%
  • litecoinLitecoin(LTC)$44.79-0.01%
  • CantonCanton(CC)$0.082276-1.10%
  • avalanche-2Avalanche(AVAX)$7.18-0.16%
  • uniswapUniswap(UNI)$5.231.05%
  • tether-goldTether Gold(XAUT)$3,848.63-0.25%
  • suiSui(SUI)$0.72-0.28%
  • USD1USD1(USD1)$1.00-0.01%
  • the-open-networkGram (prev. Toncoin)(GRAM)$1.04-2.61%
  • Ripple USDRipple USD(RLUSD)$1.000.00%
  • Global DollarGlobal Dollar(USDG)$1.00-0.01%
  • hedera-hashgraphHedera(HBAR)$0.057171-3.09%
  • Ondo US Dollar YieldOndo US Dollar Yield(USDY)$1.15-0.09%
  • paypal-usdPayPal USD(PYUSD)$1.000.07%
  • crypto-com-chainCronos(CRO)$0.0441263.19%
  • shiba-inuShiba Inu(SHIB)$0.000004-0.95%
  • BittensorBittensor(TAO)$193.570.86%
  • quant-networkQuant(QNT)$153.39-2.14%
  • Circle USYCCircle USYC(USYC)$1.140.00%
  • MemeCoreMemeCore(M)$0.875.91%
  • Spiko Amundi Overnight Swap Fund (EUR)Spiko Amundi Overnight Swap Fund (EUR)(EURSAFO)$1.12-0.05%
  • okbOKB(OKB)$86.461.32%
  • aaveAave(AAVE)$112.242.61%
  • pax-goldPAX Gold(PAXG)$3,851.28-0.22%
  • pepePepe(PEPE)$0.0000043.50%
  • Falcon USDFalcon USD(USDF)$1.000.02%
  • United StablesUnited Stables(U)$1.000.01%
TradePoint.io
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop
No Result
View All Result
TradePoint.io
No Result
View All Result

FDA approves Eli Lilly drug tirzepatide for weight loss

November 8, 2023
in Market & News
Reading Time: 4 mins read
A A
FDA approves Eli Lilly drug tirzepatide for weight loss
ShareShareShareShareShare
  • The Food and Drug Administration approved Eli Lilly’s tirzepatide drug for weight loss, paving the way for even wider use of the blockbuster medication.
  • The active ingredient in the drug, tirzepatide, has already been approved for the treatment of Type 2 diabetes under the name Mounjaro since May 2022.
  • But the FDA’s new approval means adults who have obesity or are overweight with at least one weight-related condition can use the drug, which will be marketed as Zepbound, for chronic weight management.

A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, on March 29, 2023.

George Frey | Reuters

The Food and Drug Administration on Wednesday approved Eli Lilly’s blockbuster drug tirzepatide for weight loss, paving the way for even wider use of the treatment in the U.S. 

The active ingredient in the drug, tirzepatide, has already been approved for the treatment of Type 2 diabetes under the name Mounjaro since May 2022.

YOU MAY ALSO LIKE

Twelve people injured in Florida shooting near university

Kornacki: Where Democrats see openings for Senate gains in deep-red states

But the FDA’s new approval means adults who have obesity or are overweight with at least one weight-related condition can use the drug, which will be marketed as Zepbound, for chronic weight management.

Prior to Wednesday’s approval, many patients had used tirzepatide off-label for weight loss, adding to a frenzy of demand for treatments that can help patients shed pounds, such as Novo Nordisk’s Wegovy and Ozempic. All three drugs, which carry list prices of roughly $1,000 per month, have faced supply constraints for months due to soaring demand. 

The weight loss approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding obesity drug market, which Wall Street analysts believe could grow to a $100 billion industry by 2030. The increased use of drugs has raised questions about how the changes will affect an array of industries — though it may be too early to tell how many people will use them.

The approval also comes as obesity affects an estimated 650 million adults globally and roughly 40% of the adult population in the U.S. 

“Obesity and overweight are serious conditions that can be associated with some of the leading causes of death such as heart disease, stroke and diabetes,” said Dr. John Sharretts, director of the division of diabetes, lipid disorders, and obesity in the FDA’s Center for Drug Evaluation and Research. “In light of increasing rates of both obesity and overweight in the United States, today’s approval addresses an unmet medical need.” 

Tirzepatide, works by activating two naturally produced hormones in the body: glucagon-like peptide-1, known as GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP.

The combination is said to slow the emptying of the stomach, making people feel full for longer and suppressing appetite by slowing hunger signals in the brain.

This story is developing. Please check back for updates.

Credit: Source link

ShareTweetSendSharePin

Related Posts

Twelve people injured in Florida shooting near university
Market & News

Twelve people injured in Florida shooting near university

November 17, 2026
Kornacki: Where Democrats see openings for Senate gains in deep-red states
Market & News

Kornacki: Where Democrats see openings for Senate gains in deep-red states

November 17, 2026
Adam Schiff responds to DOJ’s Alaska threat: ‘it’s Alaska’s business’ to run elections
Market & News

Adam Schiff responds to DOJ’s Alaska threat: ‘it’s Alaska’s business’ to run elections

November 17, 2026
Thrivent Mid Cap Stock Fund Q3 2026 Commentary (TMSIX)
Market & News

Thrivent Mid Cap Stock Fund Q3 2026 Commentary (TMSIX)

November 17, 2026
Next Post
Warner Bros Discovery warns hit from Hollywood strikes could linger

Warner Bros Discovery warns hit from Hollywood strikes could linger

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Search

No Result
View All Result
NVIDIA Says Permanent CEO Search Remains at Search-Firm Stage – Unite.AI

NVIDIA Says Permanent CEO Search Remains at Search-Firm Stage – Unite.AI

November 13, 2026
Bilt launches AI-powered platform to connect local businesses with new customers

Bilt launches AI-powered platform to connect local businesses with new customers

November 10, 2026
NBC Nightly News with Tom Llamas Full Episode – Oct. 27

NBC Nightly News with Tom Llamas Full Episode – Oct. 27

November 15, 2026

About

Learn more

Our Services

Legal

Privacy Policy

Terms of Use

Bloggers

Learn more

Article Links

Contact

Advertise

Ask us anything

©2020- TradePoint.io - All rights reserved!

Tradepoint.io, being just a publishing and technology platform, is not a registered broker-dealer or investment adviser. So we do not provide investment advice. Rather, brokerage services are provided to clients of Tradepoint.io by independent SEC-registered broker-dealers and members of FINRA/SIPC. Every form of investing carries some risk and past performance is not a guarantee of future results. “Tradepoint.io“, “Instant Investing” and “My Trading Tools” are registered trademarks of Apperbuild, LLC.

This website is operated by Apperbuild, LLC. We have no link to any brokerage firm and we do not provide investment advice. Every information and resource we provide is solely for the education of our readers. © 2020 Apperbuild, LLC. All rights reserved.

No Result
View All Result
  • Main
  • AI & Technology
  • Stock Charts
  • Market & News
  • Business
  • Finance Tips
  • Trade Tube
  • Blog
  • Shop

© 2023 - TradePoint.io - All Rights Reserved!